SillaJen, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (NCT05768932) | SillaJen, Inc. | 2022-12-14 |
| A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (NCT03294083) | SillaJen, Inc. | 2018-06-19 |
Track SillaJen, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.